The House Energy and Commerce Committee voted 47-11 to approve a measure that would give 12 years of market protection to brand-name biotech medicines. The amendment "takes a balanced approach between innovation, cost savings for consumers and safety," said a spokeswoman for Rep. Jay Inslee, D-Wash., one of the sponsors of the bill.

Related Summaries